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Abstract
Context—Patient-reported outcomes (PROs) provide a way to understand the effects of 
hematopoietic cell transplantation (HCT)-related stress upon patients' lives. We previously 
reported that weekly collection of PROs is feasible.
Objectives—Here, we report on the feasibility of daily patient-reported symptom collection and 
we examine the relationship between daily vs. weekly symptom reporting over time.
Methods—We analyzed data from 32 autologous and allogeneic HCT patients obtained until 
Day (D)+100. We used questions from the PRO version of the Common Terminology Criteria for 
Adverse Events to capture symptoms.
Results—We found that overall rates of daily survey completion were moderate to high (range 
67%–86%). The effect size of the difference between the maximum daily severity score and the 
weekly severity score ranged from 0.15 to 0.35, and the concordance correlation coefficient 
(CCC) ranged from 0.513 to 0.834. Concordance of daily and weekly surveys was higher for 
maximum daily severity rating and mean daily severity rating than for minimum daily severity 
rating or most recent daily severity rating.
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Conclusion—We conclude that a seven-day recall period for symptom severity provides 
acceptable accuracy and precision in the first 100 days following HCT. Further studies to explore 
the utility of daily symptom reporting within specific clinical contexts may be warranted.
Keywords
hematopoietic stem cell transplantation; patient-reported outcomes; symptom burden; PRO-
CTCAE
Introduction
Patient-reported outcomes (PROs) represent an important way to understand the effects of 
transplantation-related physiologic stress upon patients’ lives (1, 2). We previously reported 
that weekly collection of patient-reported symptoms and health-related quality of life 
(HRQOL) is feasible and provides meaningful information (3). These data quantify the 
impact of transplantation upon physiologic function over time, and discriminate groups of 
patients by the intensity of pre-transplant conditioning chemotherapy. We also demonstrated 
that the early post-transplant symptom burden has a direct correlation with physical aspects 
of HRQOL. These results were based on weekly patient recall of symptoms and HRQOL. 
However, it is not known whether meaningful daily symptom variation was missed or 
whether it is feasible to collect this information on a daily basis.
In the early post-transplant period the presence and severity of symptoms can change over 
hours to days (3). Based on cognitive theory (4) and the circumstances of the post-transplant 
period, there are reasons to believe that weekly retrospective recall of symptom experiences 
may miss changes in day-to-day symptoms that post-transplant patients experience. This 
concern has empirical support in other clinical contexts, such as urinary incontinence (5–7), 
physical activity (8, 9), and alcohol consumption (10,11), where the observed correlations of 
short-term retrospective recall and 24-hour recall have varied from 0.33 to 0.89. Additional 
work utilizing ecological momentary assessment has demonstrated moderately high group-
level correspondence between real-time and retrospective reports (of pain, for example), but 
low within-person correspondence (12, 13). Other studies comparing repetitive daily vs. 
weekly symptom reporting within specific non-cancer disease cohorts have shown 
consistency between seven-day and daily recall (4, 14), and small mean differences that 
were constant over time (15).
The purpose of the present study was to determine the feasibility of daily symptom reporting 
in the early post-transplant period, and to examine the relationship between daily and 
weekly symptom reporting over time. We hypothesized that daily symptom reporting was 
likely to be more feasible in an inpatient environment in which patients could more easily 
complete their questionnaires, as compared with an outpatient setting where patients are 
seen less frequently and receive less frequent survey completion reminders. We further 
hypothesized that, because the weekly surveys asked respondents to recall the worst severity 
of a particular symptom, the concordance of daily vs. weekly surveys would be highest for 
the maximum daily severity score within a given week for a given symptom. Last, we 
hypothesized that the concordance of daily vs. weekly surveys would be lowest during 
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periods of time and for patient populations in which symptom variability was expected to be 
greatest, such as full intensity conditioning of allogeneic transplant patients during the 
inpatient period. To test these hypotheses, we analyzed data from a prospective cohort study 
of autologous and allogeneic transplant recipients who were asked to electronically complete 
daily and weekly symptom surveys for 21 specified symptoms.
Methods
Patients
The symptom questionnaire data were collected as part of an observational pilot study 
enrolling patients undergoing HCT at the University of North Carolina (UNC) Cancer 
Hospital. Patients were recruited into autologous, reduced intensity allogeneic, or full 
intensity allogeneic cohorts, with a targeted enrollment of 10 patients per cohort. Eligibility 
criteria included age greater than 18 years and ability to read English. These patients have 
been previously described (3).
Study Design
All patients provided informed consent before enrollment using a form approved by UNC’s 
Lineberger Comprehensive Cancer Center Protocol Review Committee and UNC’s 
Biomedical Institutional Review Board. The study period was from the time of enrollment in 
the outpatient environment prior to planned hospitalization for transplantation, until day 100 
(D+100) following infusion of stem cells. Autologous HCT recipients completed daily 
symptom surveys from the first day of conditioning chemotherapy until initial hospital 
discharge. Allogeneic HCT recipients (both full intensity and reduced intensity 
conditioning) completed daily symptom surveys from the first day of conditioning 
chemotherapy until D+100. In this prospective cohort study, we chose only to have 
allogeneic rather than autologous HCT patients complete daily surveys because of the 
proximity of allogeneic HCT patients to the transplant center through D+100, and the 
anticipated logistical difficulties with daily symptom capture in autologous HCT patients 
who had since moved back to their home communities. All patients completed weekly 
symptom surveys from the first day of conditioning chemotherapy until D+100.
Measures
The National Cancer Institute’s (NCI) Patient-Reported Outcomes version of the Common 
Terminology Criteria for Adverse Events (PRO-CTCAE) measurement system allows 
patients to self-report symptomatic adverse events (AEs) (16). The items are intended to be 
complementary to items in the NCI’s CTCAE, an existing lexicon of clinician-reported 
adverse event items required for use in all NCI-sponsored trials. The PRO-CTCAE item 
library comprises 124 items that assess different attributes (e.g., presence, frequency, 
severity, interference with usual or daily activities) of 78 symptoms represented in the 
CTCAE version 4 AE lexicon. PRO-CTCAE severity items were selected for administration 
in this study. These items ask patients to rate the worst severity of a specific symptom (What 
was the severity of your [symptom] at its worst?) during the past seven days using one of 
five response choices (none, mild, moderate, severe, or very severe). Each symptom is 
scored from 0 (none) to 4 (very severe). For the purposes of this study, 21 symptom severity 
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items from the PRO-CTCAE were administered daily, using a 24-hour recall period, and 
weekly, using a seven-day recall period, according to the schedule described above. Surveys 
were administered electronically using Qualtrics Survey System (Provo, UT, USA), with 
paper-and-pencil versions available per patient preference (17), as described previously (3).
Statistical Methods
Feasibility of survey completion was assessed for all participants, and by cohort and post-
transplantation time period (two time periods from Day 0 to Day +100 were of interest: 
days/weeks prior to initial post-transplant discharge, and days/weeks following initial post-
transplant hospital discharge). To explore the relationships between daily and weekly 
symptom reporting on an individual and a group-level basis, each of the 21 symptoms was 
considered individually. In these analyses, weekly item responses were compared with 
specific descriptors of daily item responses, including mean score of the daily responses 
within the corresponding week, maximum score of the daily responses, minimum score of 
the daily responses, and Day 7 score of the daily responses (on Day 7, participants answered 
both 24-hour and weekly recall questions for each of the 21 symptoms). For these 
comparisons, differences between the weekly item scores and daily descriptors at the 
individual level were reported, as well as effect sizes, which account for the correlation 
between measures (18). The magnitude of the effect sizes were interpreted according to the 
criteria proposed by Cohen (19). For each patient, each week where a weekly survey was 
completed and three or more daily surveys also were completed was used in the analysis. 
Across all symptoms, this resulted in anywhere from 236 to 244 total weeks for analysis. 
Concordance between weekly item scores and daily descriptors also was determined by 
estimating the concordance correlation coefficient (CCC), as previously described (4). The 
CCC ranges from −1 to +1, where values closer to +1 indicate perfect agreement, values 
approaching - 1 correspond to perfect negative agreement, and values of 0 indicate no 
agreement. To interpret the CCC, we reference the criteria generally used for interpreting 
correlation statistics in PRO validation studies in which a correlation greater than 0.70 is 
considered a high level of agreement.
Results
Patient Characteristics
A total of 32 patients were enrolled into three cohorts: 10 autologous HCT recipients, 11 full 
intensity allogeneic HCT recipients, and 11 reduced intensity allogeneic HCT recipients. 
Median age of the entire population at the time of transplantation was 57.8 years. Thirteen 
patients (41%) had a high school education or less. Complete details regarding this study 
population have been previously reported (3). Two of 32 patients (6%) opted to use paper-
and-pencil only, and the rest completed daily and weekly surveys electronically.
Daily Survey Response Rates
Feasibility of weekly survey completion has been previously reported (3). For daily surveys, 
median completion percentages are shown in Table 1. Completion was calculated by 
dividing the total number of surveys that were completed by the total number that should 
have been completed by each person for a given time period. The median time to complete 
Wood et al. Page 4













21 symptom severity items for all patients was 4.4 minutes. During the initial transplant 
hospitalization, the median daily survey completion percentage for all cohorts was 86%: 
94% for the autologous transplant cohort, 87% for the reduced intensity allogeneic cohort, 
and 70% for the full intensity allogeneic cohort. Median daily survey completion 
percentages were particularly high during the first week after stem cell infusion (overall 
86%; autologous 100%, reduced intensity allogeneic 100%, full intensity allogeneic 86%), 
and remained at least 85% for each subsequent week in each cohort through D+21. 
Following discharge from the initial transplant hospitalization, median daily completion 
percentages decreased in the full intensity allogeneic cohort; median post-discharge daily 
survey completion percentages were 52% for the full intensity cohort and 86% in the 
reduced intensity cohort.
Prevalence of Daily Symptoms and Relationship of Maximum Daily Score With Weekly 
Score
Autologous patients contributed daily symptom data for a median of two weeks, reduced 
intensity allogeneic patients a median of 14 weeks, and the full intensity allogeneic patients 
a median of 10 weeks. Table 2 displays the pooled means for seven-day recalled severity 
and maximum daily severity, mean difference between seven-day recalled maximum 
severity and maximum severity 24-hour recall, effect size of that difference, and CCC for all 
symptoms. Data are pooled across cohorts and across pre- and post-transplantation discharge 
time periods. Symptoms are presented in rank order based on the proportion of the study 
weeks during which respondents had at least one daily score ≥ 1 (signifying the presence of 
that symptom for at least one of the days during that week). Throughout the entirety of the 
study period, the most consistently prevalent symptom was fatigue, with 86% of weeks 
having at least one daily fatigue score of ≥1. For each symptom, Table 2 also depicts the 
mean and standard deviation for weekly scores and the mean of the maximum daily scores 
for all respondents within a given week, over all the weeks. Effect sizes ranged from 0.15 
(cough and memory) to 0.35 (fatigue); the median effect size was 0.23. Interpreted using 
criteria proposed by Cohen, five of 21 had an effect size of less than 0.20 (negligible), and 
16 of 21 effect sizes were between 0.20 and 0.49 (small). That all of the mean differences 
were negative and small supports a conclusion that slightly higher symptom severity is 
reported when 24-hour recall is employed, compared with seven-day recall, despite the fact 
that the seven-day recall asks the respondent to report their worst severity for each of the 
symptoms over the past seven days. The CCC ranged from 0.51 (chills) to 0.83 (mouth sores 
and decreased appetite); the median CCC was 0.762. Nineteen of 21 symptoms had CCC ≥ 
0.60, and 14 of 21 had CCC ≥ 0.70, indicating a moderate to high level of agreement.
Comparisons of Weekly Scores With Specific Aspects of Daily Item Responses
Table 3 displays comparisons between additional daily score summary measures and weekly 
scores, using the CCCs. In addition to focusing on differences in maximum daily scores, 
Table 3 shows CCCs of weekly scores with the daily survey taken the same day as the 
weekly survey (Day 7), with the mean of the daily surveys for that week, and with the 
minimum of the daily surveys for that week. The five symptoms (fatigue, insomnia, loose 
stools, nausea, and decreased appetite) with the largest mean differences between maximum 
daily scores and weekly scores were selected for analysis. These data are displayed by 
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cohort and by post-transplantation time periods. In general, the greatest differences in daily 
scores and weekly scores were for the minimum daily scores, which also generally had the 
lowest CCC values. Because participants were asked to provide weekly scores that 
corresponded with the worst severity of that symptom during the week, this finding was 
expected. Weekly scores were on average less than the maximum daily scores for all 
symptoms, and greater than Day 7 scores and the mean daily scores for all symptoms. CCC 
values were generally higher for the weekly scores and the maximum daily or mean daily 
scores, rather than with the Day 7 scores. In general, CCC values were higher for all 
symptoms in the weeks after discharge than prior to discharge. In the weeks prior to 
discharge, CCC values were generally higher for reduced intensity allogeneic patients than 
full intensity allogeneic patients.
Fig. 1 displays findings from Tables 2 and 3, showing the distributions of difference scores 
(difference between maximum daily score and the corresponding weekly score for that 
week) as a function of agreement limits holding an absolute value of 0, 1, 2, 3 or 4 points. A 
score of “0” indicates that that the maximum daily scores and weekly scores for that week 
were the same. For all symptoms, there was a higher frequency of differences between 
maximum daily scores and weekly scores in the weeks prior to discharge than in the weeks 
after discharge, and the size of that difference was also larger in the pre-discharge weeks.
Discussion
In this study, we assessed the feasibility of daily symptom reporting in the early post-
transplant period and examined the concordance between daily symptom reports with 
weekly symptom reports. No prior research in HCT has compared PRO recall periods. Such 
information is important as PROs assume an increasingly prominent role in both research 
and at the point of care (20–24). Empiric knowledge of whether daily symptom reporting, 
which incurs respondent burden and requires staff resources to achieve data completeness, 
offers a more precise and accurate picture of the symptom experience, compared with seven-
day recall, and could ultimately be applied to decisions about measurement of PROs during 
and following HCT. Thus, we sought to determine whether daily symptom severity 
reporting as compared with seven-day recall offered improved precision and accuracy, and 
was likely to add benefit for the purposes of trials, research, or clinical care.
In the assessment of feasibility, we found the overall rates of survey completion were 
moderate to high (range 67 % –86%) depending on the setting. We hypothesized that daily 
symptom reporting was likely to be most complete in an inpatient environment in which 
patients had extra time to perform the surveys and availability for reminders. Conversely, we 
hypothesized that feasibility was likely to be lower in an outpatient environment, 
particularly for patients with greater illness severity or other issues requiring greater time 
investment, and for whom it was anticipated that responding to PRO surveys was likely to 
be a lower priority. We found that this was true, noting lower daily completion rates 
especially for the full intensity allogeneic transplant recipients in the post-discharge 
environment (range, 52% (full intensity allogeneic) − 86% (reduced intensity allogeneic) 
(Table 1)). Inpatient daily survey completion percentages were fairly high, with a few 
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exceptions (range, 70% –94%). It is possible that we might have achieved greater survey 
compliance with additional study personnel and regularly scheduled reminders (25).
The effect size of the difference between the maximum daily score and weekly score ranged 
across the 21 symptoms from 0.15 to 0.35, and the concordance ranged from 0.834 to 0.513. 
We found that effect size reflecting differences between maximum daily scores and weekly 
scores was highest for fatigue, with an effect size of 0.35 and CCC of 0.709. However, the 
absolute difference between the mean maximum daily score and the mean weekly score for 
fatigue was moderate (−0.35).
Because the weekly surveys asked respondents to recall the worst severity of a particular 
symptom, we hypothesized that the concordance of daily vs. weekly surveys was likely to be 
greatest for the maximum daily severity rather than other attributes of the daily surveys such 
as the minimum daily severity, mean daily severity, or the most recent (Day 7) daily rating 
of severity. Our observations supported concordance of daily vs. weekly surveys for both 
maximum daily severity and mean daily severity. Further, we hypothesized that the 
concordance of daily vs. weekly surveys was likely to be lowest during periods of time in 
which symptom variability was expected to be greatest, such as within the inpatient 
environment. Indeed, CCCs were higher after discharge.
We conclude, based on our observed concordance between daily and weekly symptom 
severity, that a seven-day recall period for symptom severity reports provides acceptable 
accuracy and precision in the first 100 days following HCT. This conclusion is supported by 
the high overall CCCs and small absolute differences between maximum daily severity and 
seven-day recalled severity for all symptoms in our study.
From a clinical care standpoint, it is possible that weekly survey reporting may miss 
information from potentially relevant daily survey reporting. In the inpatient environment, 
use of a 24-hour recall period might provide information to inform tailoring of clinical 
actions. Daily surveys might add to usual care, in which providers routinely ask patients 
about symptoms, because the full breadth, depth, and change over time of the symptom 
experience is captured by complete daily survey administration, rather than one or two 
questions asked on morning rounds. In the outpatient, less monitored environment, daily 
surveys also might offer information about less prevalent but potentially important 
symptoms that are clinically actionable. Examples of these kinds of symptoms include: 
shaking chills (a potential indicator of serious infection), loose stools or rash (potential 
indicators of graft-vs.-host disease.
Rather than recommending daily survey completion for clinical care purposes, we believe 
that further study of the clinical utility and value, balanced with the burden and cost of daily 
PRO reporting, is warranted. Specifically, additional research is needed to examine the 
extent to which daily PRO reporting influences clinical decision making in the inpatient 
environment, or earlier clinical encounters in the outpatient environment for new or 
concerning symptoms. The value of event- and context-triggered daily symptom reporting – 
i.e., initiating a series of daily symptom reports for patients in specific clinical contexts (e.g., 
Wood et al. Page 7













cytomegalovirus infection, graftvs.- host disease flare, tapering of immunosuppression) – 
also should be explored.
We believe that our results support a conclusion that weekly symptom surveys accurately 
reflect the daily symptom experience in patients who have recently undergone autologous or 
allogeneic HCT. As suggested above, further studies of patient-reported symptoms in this 
population appear to be warranted.
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Percentages of patients in whom the maximum daily scores were different than the 
corresponding weekly scores for that week, by symptom and by time period. “Pre” means 
prior to discharge from the initial transplant hospitalization and “post” means after discharge 
from the initial transplant hospitalization. The color coded numbers refer to the difference 
between the maximum daily scores and the corresponding weekly scores. A positive number 
means that the weekly score was greater than the maximum daily score during that week, 
and the magnitude corresponds to the absolute difference between the two. A negative 
number means that the weekly score was less than the maximum daily score. “0” means that 
the weekly score for that week were the same.
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Table 1
Summary (median and range) of the Percentage of HSCT Recipients (n=30) Completing Daily Symptom 
Severity Survey, by Week Post-Transplant and by Post-Transplant Phase (Inpatient Hospitalization and 












D0-D7 86 (43–100) 100 (57–100) 100 (29–100) 86 (29–100)
D8-D14 86 (29–100) 100 (43–100) 85 (14–100) 86 (14–100)
D15-D21 86 (0–100) 100 (57–100) - 86 (0–100)
D22-D50 48 (0–90) 90 (31–100) - 67 (0–100)
D51-D100 48 (0–96) 83 (0–100) - 70 (0–100)
Initial transplant hospitalization 70 (21–100) 87 (46–100) 94 (37–100) 86 (21–100)
Post-discharge 52 (0–87) 86 (46–100) - 70 (10–100)
Note: Denominators for allogeneic transplant patients are the first day of conditioning through 100 days following transplantation. The 
denominator for autologous transplant patients is the first day of conditioning through the day of discharge from the initial hospitalization
a
Autologous group did not complete daily reports following discharge.
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Fatigue 86% 1.42 (0.91) 1.77 (1.05) −0.35 0.35 0.709
Insomnia 76% 1.15 (0.91) 1.42 (0.98) −0.27 0.28 0.767
Appetite 70% 1.23 (1.07) 1.49 (1.19) −0.25 0.22 0.834
Dry Skin 67% 0.90 (0.78) 1.07 (0.83) −0.17 0.21 0.816
Itchy Skin 52% 0.64 (0.70) 0.87 (0.81) −0.23 0.30 0.659
Pain 52% 0.86 (1.01) 1.07 (1.11) −0.21 0.20 0.808
Nausea 46% 0.71 (0.94) 0.97 (1.21) −0.26 0.22 0.787
Stools 46% 0.75 (1.02) 1.02 (1.18) −0.27 0.24 0.764
Concentration 46% 0.50 (0.59) 0.68 (0.78) −0.18 0.25 0.625
Anxiety 42% 0.53 (0.72) 0.73 (0.87) −0.2 0.24 0.670
Shortness of Breath 41% 0.50 (0.69) 0.62 (0.77) −0.12 0.17 0.762
Rash 40% 0.47 (0.64) 0.68 (0.84) −0.2 0.25 0.737
Memory 40% 0.47 (0.65) 0.58 (0.76) −0.11 0.15 0.801
Abdominal Pain 35% 0.50 (0.78) 0.70 (0.95) −0.2 0.23 0.773
Dizziness 32% 0.35 (0.54) 0.47 (0.65) −0.12 0.20 0.632
Headache 29% 0.39 (0.71) 0.53 (0.83) −0.14 0.18 0.734
Sad/Unhappy Feelings 28% 0.39 (0.73) 0.61 (0.91) −0.22 0.26 0.643
Mouth Sores 28% 0.54 (1.00) 0.73 (1.17) −0.18 0.16 0.834
Chills 25% 0.33 (0.68) 0.53 (0.87) −0.21 0.26 0.513
Cough 19% 0.24 (0.56) 0.34 (0.70) −0.1 0.15 0.782
Constipation 18% 0.24 (0.59) 0.48 (0.87) −0.24 0.30 0.563
Symptoms are ranked by the percentage of weeks in the study during which there was at least one daily score of ≥1 for that symptom during that 
week. Means and standard deviations of both weekly and daily maximums are given, along with the effect size, to allow comparisons across 
symptoms. The negative numbers for the mean difference between weekly and daily maximums scores indicate the daily maximums scores were 
most often higher. The concordance correlation coefficient (CCC) shows the strength of the correlation between the maximum daily scores and 
weekly scores. A CCC of 0 demonstrates no correlation, and a CCC of +1 demonstrates perfect correlation.
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